Breaking Down Triumph Science & Technology Co.,Ltd Financial Health: Key Insights for Investors

Curious whether Triumph Science & Technology Co., Ltd. (600552.SS) is a resilient play or a risky bet? Our deep-dive peels back the numbers: 2024 revenue was 4.89 billion yuan (down 2.32% y/y) while TTM revenue per share stood at 5.18 yuan with quarterly revenue growth of 0.10%, and the company posted 4.31 billion yuan in revenue for the first three quarters of 2025 (up 20.6% y/y); segment detail shows display materials driving 3.656 billion yuan (up 7.65%) as applied materials slid to 1.238 billion yuan (down 23.29%), revenue per employee hit 957,510 yuan, net income rose to 140.16 million yuan in 2024 (+30.76% y/y) with TTM EPS of 0.16 yuan and quarterly earnings growth of 73% y/y, margins include a TTM gross margin of 17.21%, net margin of 3.07% and operating margin of 3.39%, returns show ROA at 0.83% and ROE at 4.32%; balance-sheet and leverage snapshots list total assets of 11.98 billion yuan vs. liabilities of 7.33 billion yuan (debt/equity ~1.57 as of 31-Mar-2025), while earlier year-end figures show total debt ~3.45 billion yuan and stockholders' equity ~4.17 billion yuan (net debt-to-equity ~0.76); liquidity and cash highlight a current ratio of 1.11, quick ratio of 0.57, operating cash flow of 144.44 million yuan but free cash flow of -867.74 million yuan, and valuation metrics as of 1-Jul-2025 put market cap at 10.67 billion yuan with a trailing P/E of 70.63, forward P/E of 41.85, P/S 2.18, P/B 2.55, EV/Revenue 3.06 and EV/EBITDA 26.41-read on for a section-by-section breakdown of revenue trends, profitability, debt structure, liquidity and valuation to inform your investor view.

Triumph Science & Technology Co.,Ltd (600552.SS) Revenue Analysis

Triumph Science & Technology reported total revenue of 4.89 billion yuan in 2024, a slight decline of 2.32% from 5.01 billion yuan in 2023. Revenue trends into 2025 show stabilization and recovery in the first three quarters, driven primarily by the display materials business.

• 2024 total revenue: 4.89 billion yuan (-2.32% vs. 2023)
• TTM revenue per share (ended Mar 2025): 5.18 yuan
• Quarterly revenue growth (most recent quarter): +0.10%
• Revenue first 3 quarters 2025: 4.31 billion yuan (+20.6% YoY)
• Revenue per employee: 957,510 yuan

Segment performance in 2024:

• Display materials: operating income 3.656 billion yuan, +7.65% YoY
• Applied materials: revenue 1.238 billion yuan, -23.29% YoY

For strategic context and corporate direction, see Mission Statement, Vision, & Core Values (2026) of Triumph Science & Technology Co.,Ltd.

Triumph Science & Technology Co.,Ltd (600552.SS) - Profitability Metrics

Triumph Science & Technology Co.,Ltd (600552.SS) shows improving profitability in recent reporting periods, with notable year-over-year growth in net income and quarterly earnings acceleration. Key margin and return metrics for the trailing twelve months (TTM) ended March 2025 and full-year 2024 figures are summarized below.

• Net income (2024): 140.16 million yuan, up 30.76% from 107.17 million yuan in 2023.
• TTM net profit margin (ended Mar 2025): 3.07%.
• TTM operating margin (ended Mar 2025): 3.39%.
• TTM gross profit margin (ended Mar 2025): 17.21%.
• TTM EPS (ended Mar 2025): 0.16 yuan; quarterly EPS growth: 73.00% YoY.
• TTM ROA (ended Mar 2025): 0.83%; TTM ROE: 4.32%.

For background on corporate structure, history and how Triumph Science & Technology generates revenue, see: Triumph Science & Technology Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Triumph Science & Technology Co.,Ltd (600552.SS) Debt vs. Equity Structure

Key balance-sheet snapshots and leverage metrics for Triumph Science & Technology Co.,Ltd highlight changes in asset base, liability load and debt composition across recent reporting dates. The figures below are presented to compare total assets, total liabilities, total debt, net debt and shareholders' equity along with computed leverage ratios.

• Total-asset scale reached ¥11.98 billion by 2025-03-31 with equity of ¥4.65 billion (assets minus liabilities).
• End-2024 profile shows total debt of ¥3.45 billion against equity of ¥4.17 billion (debt-to-equity ≈ 0.83 when using debt only; overall liabilities produce a higher leverage of 1.59).
• Net debt at 2024 year-end was ¥3.15 billion, yielding a net-debt-to-equity of ≈ 0.76 - indicating interest-bearing obligations net of cash are materially below equity.
• Comparative 2023 figures: total debt ¥3.65 billion and equity ¥4.08 billion (debt-to-equity ≈ 0.89) with total liabilities-to-equity ≈ 1.41.

Observed dynamics:

• Liabilities-to-equity ratios (1.41 in 2023 → 1.59 in 2024 → 1.57 in 2025-03-31) show a rise into 2024 and slight reduction by Q1 2025 driven by asset growth and/or changes in liability composition.
• Debt-only leverage (0.89 in 2023 → 0.83 in 2024) and net-debt-to-equity (~0.76 at 2024 year-end) point to a modest improvement in funded leverage when isolating interest-bearing obligations and cash.

For additional context on Triumph Science & Technology's corporate background and how these financials relate to its operating model, see: Triumph Science & Technology Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Triumph Science & Technology Co.,Ltd (600552.SS) - Liquidity and Solvency

• Current ratio (Mar 31, 2025): 1.11 - adequate overall short-term coverage.
• Quick ratio (Mar 31, 2025): 0.57 - potential short-term liquidity pressure absent inventory sales.
• Operating cash flow (FY2024): ¥144.44 million - operations generated positive cash.
• Free cash flow (FY2024): ¥-867.74 million - large negative FCF, likely from CAPEX, acquisitions, or working capital build.
• Net income (FY2024): ¥140.16 million - +30.76% YoY from ¥107.17 million (FY2023).
• Trailing 12-month margins (ended Mar 2025): net margin 3.07%; operating margin 3.39% - profitable but thin margins.

• Liquidity: Current ratio >1 provides cushion, but quick ratio <1 elevates the importance of inventory turnover and receivables collection.
• Cash flow dynamics: Positive operating cash flow indicates core business cash generation, yet the large negative FCF suggests significant investing activities (CAPEX, R&D, expansion) or working capital increases that may pressure balance-sheet flexibility.
• Profitability vs. cash: Net income growth (+30.76% YoY) with low single-digit margins shows revenue/profit growth but modest conversion to free cash; monitor capex plans and financing needs.
• Risk factors: If inventory or receivables cannot be converted quickly, short-term liquidity may tighten; sustained negative FCF could require external financing or asset sales.

Triumph Science & Technology Co.,Ltd (600552.SS) - Valuation Analysis

As of July 1, 2025, Triumph Science & Technology Co.,Ltd (600552.SS) presents a valuation profile characterized by elevated earnings multiples, modest profitability margins and balance-sheet metrics that reflect a growth-orientated market pricing. The headline market cap and multiple data highlight investor expectations for future earnings expansion despite current modest returns.

• Market capitalization: 10.67 billion yuan (as of 2025-07-01).
• Trailing P/E: 70.63; Forward P/E: 41.85 - indicating significant premium to current earnings and expected earnings acceleration priced in by the market.
• Price-to-Sales (TTM): 2.18; Price-to-Book (most recent quarter): 2.55 - suggesting investors pay above book value and assign revenue multiple above 2x.
• Enterprise Value / Revenue: 3.06; EV / EBITDA: 26.41 - enterprise-level valuation implies a high multiple on operating cashflow.
• EPS (TTM ending Mar 2025): 0.16 yuan; Quarterly earnings growth: +73.00% YoY - recent quarter shows strong sequential earnings acceleration.
• ROA (TTM ending Mar 2025): 0.83%; ROE: 4.32% - returns on assets and equity remain low relative to valuation multiples.
• Net profit margin (TTM ending Mar 2025): 3.07%; Operating margin: 3.39% - margins are thin, indicating limited current profitability per revenue.

For further context on ownership, institutional flows and shareholder composition that influence valuation dynamics, see: Exploring Triumph Science & Technology Co.,Ltd Investor Profile: Who's Buying and Why?

Triumph Science & Technology Co.,Ltd (600552.SS) - Risk Factors

Key financial signals

• Quick ratio (Mar 31, 2025): 0.57 - indicates limited ability to cover short‑term liabilities without relying on inventory sales or fresh financing.
• Free cash flow (FY ended Dec 31, 2024): -867.74 million RMB - negative FCF that may pressure liquidity, capital expenditure plans and dividend capacity.
• Profitability (TTM ended Mar 2025): Net profit margin 3.07%; Operating margin 3.39% - thin margins that reduce buffer against cost shocks and demand volatility.

Primary risk implications

• Liquidity crunch: Quick ratio below 1.0 increases reliance on inventory liquidation, receivable collection acceleration or external funding to meet near‑term payables.
• Negative FCF sustainability: -867.74M RMB suggests the company consumed cash after operations and investments; continued negative FCF can deplete reserves and raise refinancing needs.
• Margin vulnerability: Net and operating margins near ~3% leave limited room for raw material inflation, pricing pressure or increased SG&A without eroding profits.
• Refinancing and covenant risk: Weak cash generation and low quick ratio heighten the risk of covenant breaches or more expensive debt on refinancing.
• Investment and growth constraints: Capital allocation (R&D, capex, M&A) may be constrained if cash flow recovery is slow, impairing competitive positioning.
• Market sentiment and equity risk: Persistent negative FCF and slim margins can depress investor confidence and heighten equity volatility.
• Operational sensitivity: Supply‑chain disruption or demand softness could quickly convert thin operating margins into losses.

Secondary and context risks

• Working capital strain - receivables/inventory management becomes critical given low quick ratio.
• Interest rate and macro exposure - higher borrowing costs amplify refinancing burden on negative FCF.
• Customer concentration or sector cyclicality - any slowdown among major customers may disproportionately impact revenues.
• Regulatory/competitive risk - policy changes or aggressive pricing from competitors could compress margins further.

For background on the company's strategy, structure and business model see Triumph Science & Technology Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Triumph Science & Technology Co.,Ltd (600552.SS) - Growth Opportunities

Triumph Science & Technology's 2024 operating results and TTM margins through March 2025 highlight clear pockets of strength and areas that can unlock upside with targeted execution.

• Display materials: operating income of ¥3.656 billion in 2024, up 7.65% year-over-year - signaling sustained demand and scalable revenue potential.
• Applied materials: revenue of ¥1.238 billion in 2024, down 23.29% YoY - a segment where recovery initiatives or product mix optimization could drive outsized improvement.
• Profitability trajectory: net profit margin (TTM Mar‑2025) at 3.07% and operating margin at 3.39% - room for margin expansion via cost control, higher-margin products, and capacity utilization.

Key actionable growth levers:

• Expand higher-margin display materials offerings and capture share in advanced display supply chains where the company already shows momentum.
• Revitalize applied materials via R&D, customer re-engagement, or strategic partnerships to stem the 23.29% decline and return the segment to growth.
• Improve margins through scale, automation, procurement leverage, and product mix shift toward specialty, premium materials.
• Target international diversification to reduce cyclicality tied to regional demand swings.

Potential catalysts and monitoring signals investors should watch:

• New contracts or OEM approvals in display panels and related supply chains.
• Quarterly margin expansion (operating margin moving above 5% would indicate meaningful progress).
• Recovery trends in applied materials revenue and sequential improvement in segment margins.
• Capex or capacity-utilization disclosures that indicate scaling of high-margin lines.

For additional context on ownership and investor interest, see: Exploring Triumph Science & Technology Co.,Ltd Investor Profile: Who's Buying and Why?